Cyclooxygenase as a target for chemoprevention in colorectal cancer: Lost cause or a concept coming of age?

Expert Opinion on Therapeutic Targets

Volumn 13, Issue 2, 2009, Pages 209-218

  Doherty, Glen A ^a   Murray, Frank E ^a  

^a BEAUMONT HOSPITAL   (Ireland)

Author keywords

Chemoprevention; Colorectal cancer; COX; Prostaglandin

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; FOLIC ACID; LUMIRACOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PLACEBO; PROSTAGLANDIN SYNTHASE; ROFECOXIB; VALDECOXIB; ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2; PROSTAGLANDIN SYNTHASE INHIBITOR;

ADENOMATOUS POLYP; ANEMIA; CANCER PREVENTION; CANCER THERAPY; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLORECTAL ADENOMA; COLORECTAL CANCER; COLORECTAL CARCINOMA; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL IRRITATION; GASTROINTESTINAL OBSTRUCTION; GASTROINTESTINAL SYMPTOM; HUMAN; NONHUMAN; OSTEOARTHRITIS; PAIN; REVIEW; RHEUMATOID ARTHRITIS; ULCER; ANIMAL; COLORECTAL TUMOR; DISEASE MODEL; DRUG DELIVERY SYSTEM; DRUG EFFECT; ENZYMOLOGY; METABOLISM;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; HUMANS;

EID: 64349089725     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728220802653631     Document Type: Review

References (99)

1. Boyle P, Leon ME. Epidemiology of colorectal cancer. Br Med Bull 2002 ; 64 : 1-25 (Pubitemid 35238576)
2. Fernandez E, La Vecchia C, Gonzalez JR, et al. Converging patterns of colorectal cancer mortality in Europe. Eur J Cancer 2005 ; 41 : 430-437 (Pubitemid 40187215)
3. Ciccolallo L, Capocaccia R, Coleman MP, et al. Survival differences between European and US patients with colorectal cancer: role of stage at diagnosis and surgery. Gut 2005 ; 54 : 268-273 (Pubitemid 40139245)
4. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988 ; 319 : 525-532 (Pubitemid 18215829)
5. Sheehan KM, O'connell F, O'grady A, et al. The relationship between cyclooxygenase-2 expression and characteristics of malignant transformation in human colorectal adenomas. Eur J Gastroenterol Hepatol 2004 ; 16 : 619-625 (Pubitemid 38703872)
6. Groden J, Thliveris A, Samowitz W, et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 1991 ; 66 : 589-600 (Pubitemid 121001394)
7. Lynch HT, de la Chapelle A. Genetic susceptibility to non-polyposis colorectal cancer. J Med Genet 1999 ; 36 : 801-818 (Pubitemid 29520569)
8. Liu B, Parsons R, Papadopoulos N, et al. Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients. Nat Med 1996 ; 2 : 169-174 (Pubitemid 26057553)
9. Risch N. The genetic epidemiology of cancer: interpreting family and twin studies and their implications for molecular genetic approaches. Cancer Epidemiol Biomarkers Prev 2001 ; 10 : 733-741 (Pubitemid 32695152)
10. Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer - analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000 ; 343 : 78-85 (Pubitemid 30451850)
11. Lin HJ, Lakkides KM, Keku TO, et al. Prostaglandin H synthase 2 variant (Val511Ala) in African Americans may reduce the risk for colorectal neoplasia. Cancer Epidemiol Biomarkers Prev 2002 ; 11 : 1305-1315 (Pubitemid 35340365)
12. Papafili A, Hill MR, Brull DJ, et al. Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol 2002 ; 22 : 1631-1636
13. Cipollone F, Toniato E, Martinotti S, et al. A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. Jama 2004 ; 291 : 2221-2228 (Pubitemid 38608171)
14. Ulrich CM, Whitton J, Yu JH, et al. PTGS2 (COX-2) -765G > C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs. Cancer Epidemiol Biomarkers Prev 2005 ; 14 : 616-619
15. Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology 2003 ; 124 : 544-560 (Pubitemid 36169269)
16. Bhattacharyya DK, Lecomte M, Rieke CJ, et al. Involvement of arginine 120, glutamate 524, and tyrosine 355 in the binding of arachidonate and 2-phenylpropionic acid inhibitors to the cyclooxygenase active site of ovine prostaglandin endoperoxide H synthase-1. J Biol Chem 1996 ; 271 : 2179-2184 (Pubitemid 26047808)
17. Luong C, Miller A, Barnett J, et al. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nat Struct Biol 1996 ; 3 : 927-933 (Pubitemid 26398325)
18. Kargman S, Charleson S, Cartwright M, et al. Characterization of Prostaglandin G/H Synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology 1996 ; 111 : 445-454 (Pubitemid 26256734)
19. Mizuno H, Sakamoto C, Matsuda K, et al. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 1997 ; 112 : 387-397 (Pubitemid 27078825)
20. Nowak J, Fitzgerald GA. In vivo formation of prostacyclin and thromboxane A2 at the site of platelet-vascular interaction in humans. Adv Prostaglandin Thromboxane Leukot Res 1987 ; 17A : 208-211
21. Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 2004 ; 56 : 387-437 (Pubitemid 39096597)
22. Williams CS, Luongo C, Radhika A, et al. Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology 1996 ; 111 : 1134-1140 (Pubitemid 26327618)
23. Jacoby RF, Marshall DJ, Newton MA, et al. Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res 1996 ; 56 : 710-714 (Pubitemid 26055457)
24. Chulada PC, Thompson MB, Mahler JF, et al. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 2000 ; 60 : 4705-4708 (Pubitemid 30701474)
25. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996 ; 87 : 803-809 (Pubitemid 26404280)
26. DuBois RN, Radhika A, Reddy BS, Entingh AJ. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology 1996;110:1259-1262 (Pubitemid 26113767)
27. Reddy BS, Rao CV, Rivenson A, Kelloff G. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 1993 ; 14 : 1493-1497 (Pubitemid 23249348)
28. Yoshimi N, Shimizu M, Matsunaga K, et al. Chemopreventive effect of N-(2-cyclohexyloxy-4-nitrophenyl)methane sulfonamide (NS-398), a selective cyclooxygenase-2 inhibitor, in rat colon carcinogenesis induced by azoxymethane. Jpn J Cancer Res 1999 ; 90 : 406-412 (Pubitemid 29213545)
29. Sheng H, Shao J, Kirkland SC, et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997 ; 99 : 2254-2259 (Pubitemid 27203783)
30. Pugh S, Thomas GA. Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2. Gut 1994 ; 35 : 675-678 (Pubitemid 24163797)
31. Hansen-Petrik MB, McEntee MF, Jull B, et al. Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice. Cancer Res 2002 ; 62 : 403-408
32. Kawamori T, Uchiya N, Sugimura T, Wakabayashi K. Enhancement of colon carcinogenesis by prostaglandin E2 administration. Carcinogenesis 2003 ; 24 : 985-990 (Pubitemid 36748916)
33. Sheng H, Shao J, Washington MK, DuBois RN. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 2001 ; 276 : 18075-18081 (Pubitemid 37411372)
34. Yoshimoto T, Takahashi Y, Kinoshita T, et al. Growth stimulation and epidermal growth factor receptor induction in cyclooxygenase-overexpressing human colon carcinoma cells. Adv Exp Med Biol 2002 ; 507 : 403-407 (Pubitemid 37330212)
35. Shao J, Lee SB, Guo H, et al. Prostaglandin E2 stimulates the growth of colon cancer cells via induction of amphiregulin. Cancer Res 2003 ; 63 : 5218-5223 (Pubitemid 37139831)
36. Pai R, Soreghan B, Szabo IL, et al. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002 ; 8 : 289-293 (Pubitemid 34250108)
37. Sheng H, Shao J, Morrow JD, et al. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998 ; 58 : 362-366 (Pubitemid 28047080)
38. Tang X, Sun YJ, Half E, et al. Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells. Cancer Res 2002 ; 62 : 4903-4908 (Pubitemid 34984412)
39. Sun Y, Tang XM, Half E, et al. Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells. Cancer Res 2002 ; 62 : 6323-6328 (Pubitemid 35244488)
40. Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998 ; 93 : 705-716 (Pubitemid 28257578)
41. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000 ; 60 : 1306-1311 (Pubitemid 30151999)
42. Williams CS, Tsujii M, Reese J, et al. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000 ; 105 : 1589-1594 (Pubitemid 30390309)
43. Dormond O, Bezzi M, Mariotti A, Ruegg C. Prostaglandin E2 promotes integrin alpha Vbeta 3-dependent endothelial cell adhesion, rac-activation, and spreading through cAMP/PKA-dependent signaling. J Biol Chem 2002 ; 277 : 45838-45846 (Pubitemid 35417562)
44. Dormond O, Foletti A, Paroz C, Ruegg C. NSAIDs inhibit alpha V beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis. Nat Med 2001 ; 7 : 1041-1047 (Pubitemid 32937385)
45. Yao M, Lam EC, Kelly CR, et al. Cyclooxygenase-2 selective inhibition with NS-398 suppresses proliferation and invasiveness and delays liver metastasis in colorectal cancer. Br J Cancer 2004 ; 90 : 712-719 (Pubitemid 38297215)
46. Hull MA, Fenwick SW, Chapple KS, et al. Cyclooxygenase-2 expression in colorectal cancer liver metastases. Clin Exp Metastasis 2000 ; 18 : 21-27 (Pubitemid 32096045)
47. Tsujii M, Kawano S, Dubois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997 ; 94 : 3336-3340 (Pubitemid 27157312)
48. Zeytin HE, Patel AC, Rogers CJ, et al. Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice. Cancer Res 2004 ; 64 : 3668-3678 (Pubitemid 38657947)
49. Pockaj BA, Basu GD, Pathangey LB, et al. Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer. Ann Surg Oncol 2004 ; 11 : 328-339 (Pubitemid 40486775)
50. Karnes WE Jr, Shattuck-Brandt R, Burgart LJ, et al. Reduced COX-2 protein in colorectal cancer with defective mismatch repair. Cancer Res 1998 ; 58 : 5473-5477 (Pubitemid 28551132)
51. Lee SH, Williams MV, Dubois RN, Blair IA. Cyclooxygenase-2-mediated DNA damage. J Biol Chem 2005 ; 280 : 28337-28346 (Pubitemid 41105731)
52. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971 ; 231 : 232-235
53. Eberhart CE, Coffey RJ, Radhika A, et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994 ; 107 : 1183-1188 (Pubitemid 24294584)
54. Sheehan KM, Sheahan K, O'donoghue DP, et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. Jama 1999 ; 282 : 1254-1257
55. Roth GJ, Machuga ET, Ozols J. Isolation and covalent structure of the aspirin-modified, active-site region of prostaglandin synthetase. Biochemistry 1983 ; 22 : 4672-4675
56. Gridley G, McLaughlin JK, Ekbom A, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993 ; 85 : 307-311 (Pubitemid 23068804)
57. Giovannucci E, Rimm EB, Stampfer MJ, et al. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994 ; 121 : 241-246
58. Giovannucci E, Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995 ; 333 : 609-614
59. Chan AT, Giovannucci EL, Meyerhardt JA, et al. Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology 2008 ; 134 : 21-28 (Pubitemid 350309311)
60. Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007 ; 369 : 1603-1613 (Pubitemid 46710123)
61. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003 ; 348 : 891-899 (Pubitemid 36297997)
62. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003 ; 348 : 883-890 (Pubitemid 36297996)
63. Benamouzig R, Deyra J, Martin A, et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-yea results of the APACC trial. Gastroenterology 2003 ; 125 : 328-336 (Pubitemid 36929412)
64. Logan RF, Grainge MJ, Shepherd VC, et al. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology 2008 ; 134 : 29-38 (Pubitemid 350309319)
65. Imperiale TF. Aspirin and the prevention of colorectal cancer. N Engl J Med 2003 ; 348 : 879-880 (Pubitemid 36297994)
66. Suleiman S, Rex DK, Sonnenberg A. Chemoprevention of colorectal cancer by aspirin: a cost-effectiveness analysis. Gastroenterology 2002 ; 122 : 78-84 (Pubitemid 34049197)
67. Lance P. Chemoprevention for colorectal cancer: some progress but a long way to go. Gastroenterology 2008 ; 134 : 341-343 (Pubitemid 350309344)
68. Soll AH, Weinstein WM, Kurata J, McCarthy D. Nonsteroidal anti-inflammatory drugs and peptic ulcer disease. Ann Intern Med 1991 ; 114 : 307-319
69. Ehrich EW, Dallob A, De Lepeleire I, et al. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther 1999 ; 65 : 336-347 (Pubitemid 29142940)
70. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000 ; 343 : 1520 -8, 2 p following 28 (Pubitemid 30844348)
71. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. Jama 2000 ; 284 : 1247-1255 (Pubitemid 30691365)
72. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-1952 (Pubitemid 30419089)
73. Rahme E, Barkun AN, Toubouti Y, Bardou M. The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence. Gastroenterology 2003 ; 125 : 404-412 (Pubitemid 36929421)
74. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005 ; 352 : 1092-1102 (Pubitemid 40365350)
75. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005 ; 352 : 1081-1091 (Pubitemid 40365349)
76. Solomon SD, Mcmurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005 ; 352 : 1071-1080 (Pubitemid 40365348)
77. McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999 ; 96 : 272-277 (Pubitemid 29036089)
78. Baron JA, Sandler RS, Bresalier RS, et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006 ; 131 : 1674-1682 (Pubitemid 44958508)
79. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006 ; 355 : 873-884 (Pubitemid 44315980)
80. Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006 ; 355 : 885-895 (Pubitemid 44315981)
81. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials BMJ 2006 ; 332 : 1302-1308
82. Kahi CJ, Rex DK, Imperiale TF. Screening, surveillance, and primary prevention for colorectal cancer: a review of the recent literature. Gastroenterology 2008 ; 135 : 380-399
83. Alberts DS, Martinez ME, Hess LM, et al. Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. J Natl Cancer Inst 2005 ; 97 : 846-853 (Pubitemid 40909127)
84. Schatzkin A, Lanza E, Corle D, et al. Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group. N Engl J Med 2000 ; 342 : 1149-1155
85. Cole BF, Baron JA, Sandler RS, et al. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA 2007 ; 297 : 2351-2359 (Pubitemid 46883748)
86. Baron JA, Beach M, Mandel JS, et al. Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. N Engl J Med 1999 ; 340 : 101-107
87. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006 ; 296 : 1633-1644 (Pubitemid 44511610)
88. Dube C, Rostom A, Lewin G, et al. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 2007 ; 146 : 365-375
89. Rostom A, Dube C, Lewin G, et al. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the US Preventive Services Task Force. Ann Intern Med 2007 ; 146 : 376-389 (Pubitemid 351650598)
90. Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med 2007 ; 146 : 361-364 (Pubitemid 351650596)
91. Abraham NS, El-Serag HB, Hartman C, et al. Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident. Aliment Pharmacol Ther 2007 ; 25 : 913-924 (Pubitemid 46525353)
92. Martinez ME, O'brien TG, Fultz KE, et al. Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. Proc Natl Acad Sci USA 2003 ; 100 : 7859-7864
93. Accioly MT, Pacheco P, Maya-Monteiro CM, et al. Lipid bodies are reservoirs of cyclooxygenase-2 and sites of prostaglandin-E2 synthesis in colon cancer cells. Cancer Res 2008 ; 68 : 1732-1740
94. Kanai N, Lu R, Satriano JA, et al. Identification and characterization of a prostaglandin transporter. Science 1995 ; 268 : 866-869
95. Mutoh M, Watanabe K, Kitamura T, et al. Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res 2002 ; 62 : 28-32
96. Sonoshita M, Takaku K, Sasaki N, et al. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat Med 2001 ; 7 : 1048-1051 (Pubitemid 32937386)
97. Hull MA, Ko SC, Hawcroft G. Prostaglandin EP receptors: targets for treatment and prevention of colorectal cancer? Mol Cancer Ther 2004 ; 3 : 1031-1039
98. Subbaramaiah K, Benezra R, Hudis C, Dannenberg AJ. Cyclooxygenase-2 derived prostaglandin E2 stimulates Id-1 transcription. J Biol Chem 2008 ; 283 (49): 33955-33968
99. Tuynman JB, Vermeulen L, Boon EM, et al. Cyclooxygenase-2 inhibition inhibits c-Met kinase activity and Wnt activity in colon cancer. Cancer Res 2008 ; 68 : 1213-1220 (Pubitemid 351272241)